Caprock Group LLC Invests $66,000 in AEON Biopharma, Inc. (NASDAQ:AEON)

Caprock Group LLC acquired a new stake in shares of AEON Biopharma, Inc. (NASDAQ:AEON) during the 3rd quarter, Holdings Channel.com reports. The fund acquired 62,686 shares of the company’s stock, valued at approximately $66,000.

Separately, Vanguard Group Inc. grew its position in AEON Biopharma by 261.8% in the 1st quarter. Vanguard Group Inc. now owns 758,992 shares of the company’s stock worth $8,804,000 after purchasing an additional 549,207 shares during the period. Institutional investors and hedge funds own 22.78% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $5.00 price target on shares of AEON Biopharma in a research note on Tuesday, October 1st.

AEON Biopharma Stock Up 4.9 %

NASDAQ AEON opened at $0.56 on Tuesday. The company has a 50-day moving average price of $0.89 and a 200-day moving average price of $1.20. AEON Biopharma, Inc. has a 52 week low of $0.52 and a 52 week high of $17.17. The firm has a market capitalization of $22.23 million, a P/E ratio of 3.09 and a beta of 0.40.

About AEON Biopharma

AEON Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder.